Treatment-Resistant Unipolar Depression and Adjunctive Therapy
neuroscienceCME Medical Simulation
Premiere Date: Friday, May 4, 2012This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, May 4, 2013
Note: Credit Is No Longer Available
| Paul E. Holtzheimer, MD Associate Professor Psychiatry and Surgery Director, Mood Disorders Service Dartmouth Medical School Dartmouth Hitchcock Medical Center Lebanon, NH |
Despite the high prevalence of major depressive disorder (MDD) and the availability of effective treatments, only one-third of patients experience remission of depression.(1) While many patients show improvement with initial therapy, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial demonstrated that this improvement is not to the level of remission or recovery.(2) Adjunctive therapy is particularly helpful in managing patients who have experienced a partial response to their initial treatment. The adjunctive use of atypical antipsychotic agents has increased for patients who do not achieve full remission with traditional antidepressants.
This evidence-based, neuroscienceCME Medical Simulation puts the clinician—the life-long learner—into the “driver’s seat” as the decision-maker who is providing care for a patient across two or three clinical encounters. As such, clinicians have the opportunity to put their knowledge into practice with this virtual patient, and then translate their experiences to their practices with actual patients. This simulation allows clinicians to explore adjunctive treatment strategies and choose individualized treatment plans for patients with treatment-resistant major depression.
- Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179-200. PMID: 8827185.
- Rush AJ, Warden D, Wisniewski, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23(8):627-647. PMID: 19594193.
The goal of this activity is to inform physicians who treat patients with treatment-resistant depression that there are options for adjunctive pharmacotherapeutic approaches.
At the end of this CE activity, participants should be able to:
- Tailor individualized treatment plans for patients with major depressive disorder according to the “best fit” of patient needs and pharmacological profiles for evidence-based, therapeutic options.
- Implement a strategy for the ongoing management of treatment-resistant unipolar depression—one that optimizes pharmacotherapy and integrates psychotherapy with a goal of sustained remission.
Supported in part by an educational grant from AstraZeneca, LP
Supported in part by CME Outfitters, LLC
Physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other nonphysician health care professionals interested in treatment-resistant depression.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1 contact hour.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1 contact hour (0.1 CEU)
Universal Activity Number: 0376-0000-12-010-H01-P (recorded programs)
Type: application-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/test (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Holtzheimer has disclosed that he receives grants/research support from the National Institute of Mental Health. He serves as a consultant to St. Jude Medical Neuromodulation.
Tony Graham, MD (Content/peer reviewer) has no disclosures to report.
Ruth Cody, BSN, RN-BC (Content/peer reviewer) has no disclosures to report.
Nancy Jennings, MSN, MBA, MHA, RNC (Content/peer reviewer) has no disclosures to report.
Sepanta Jalali, MD (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Joy B. Leffler, MLA, NASW CSE (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and AstraZeneca, L.P. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PL-024-050412-13
